SEPN SEPTERNA INC

Septerna to Present at Jefferies Global Healthcare Conference

Septerna to Present at Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York.

A live webcast of the presentation will be available and in the investors section of the company’s website at . The webcast will be archived for at least 30 days following the presentation.

About Septerna

Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit .

Investor Contact:

Renee Leck

THRUST Strategic Communications



EN
29/05/2025

Underlying

SEPNSEPTERNA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEPTERNA INC

 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT in San Francisco. A live webcast of the presentation will be available in the investors section of the co...

December 17, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Septerna to Participate in 8th Annual Evercore Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 a.m. ET in Coral Gables, Florida. A live webcast of the presentation will be available in the investors section of the company’s website at . The webcast will be...

November 25, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Highlights Company Progress and Reports Third Quarter 2025 Fi...

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming m...

November 10, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Participate in Upcoming Investor Conferences

Septerna to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside chat on Monday, November 10, 2025, at 4:00 p.m. ET TD Cowen Immunology & Inflammation SummitFireside chat on Wednesday, November 12, 2025, at 4:00 p.m. ET L...

November 3, 2025 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D...

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D ...

September 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch